Faina Nakhlis1,2, Lauren Gilmore3, Rebecca Gelman1, Isabelle Bedrosian4, Kandice Ludwig5, E Shelley Hwang6, Shawna Willey7, Clifford Hudis8, J Dirk Iglehart1,2, Elizabeth Lawler1, Nicole Y Ryabin1, Mehra Golshan1,2, Stuart J Schnitt9, Tari A King10. 1. Dana-Farber/Harvard Cancer Center, Boston, MA, USA. 2. Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. 3. Mount Auburn Hospital, Cambridge, MA, USA. 4. University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Indiana University Cancer Center, Indianapolis, IN, USA. 6. Duke University Medical Center, Durham, NC, USA. 7. Georgetown University Cancer Center, Washington, DC, USA. 8. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 10. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tking7@partners.org.
Abstract
BACKGROUND: Lobular neoplasia (LN) represents a spectrum of atypical proliferative lesions, including atypical lobular hyperplasia and lobular carcinoma-in-situ. The need for excision for LN found on core biopsy (CB) is controversial. We conducted a prospective multi-institutional trial (TBCRC 20) to determine the rate of upgrade to cancer after excision for pure LN on CB. METHODS: Patients with a CB diagnosis of pure LN were prospectively identified and consented to excision. Cases with discordant imaging and those with additional lesions requiring excision were excluded. Upgrade rates to cancer were quantified on the basis of local and central pathology review. Confidence intervals and sample size were based on exact binomial calculations. RESULTS: A total of 77 of 79 registered patients underwent excision (median age 51 years, range 27-82 years). Two cases (3%; 95% confidence interval 0.3-9) were upgraded to cancer (one tubular carcinoma, one ductal carcinoma-in-situ) at excision per local pathology. Central pathology review of 76 cases confirmed pure LN in the CB in all but two cases. In one case, the tubular carcinoma identified at excision was also found in the CB specimen, and in the other, LN was not identified, yielding an upgrade rate of one case (1%; 95% CI 0.01-7) by central pathology review. CONCLUSIONS: In this prospective study of 77 patients with pure LN on CB, the upgrade rate was 3% by local pathology and 1% by central pathology review, demonstrating that routine excision is not indicated for patients with pure LN on CB and concordant imaging findings.
BACKGROUND:Lobular neoplasia (LN) represents a spectrum of atypical proliferative lesions, including atypical lobular hyperplasia and lobular carcinoma-in-situ. The need for excision for LN found on core biopsy (CB) is controversial. We conducted a prospective multi-institutional trial (TBCRC 20) to determine the rate of upgrade to cancer after excision for pure LN on CB. METHODS:Patients with a CB diagnosis of pure LN were prospectively identified and consented to excision. Cases with discordant imaging and those with additional lesions requiring excision were excluded. Upgrade rates to cancer were quantified on the basis of local and central pathology review. Confidence intervals and sample size were based on exact binomial calculations. RESULTS: A total of 77 of 79 registered patients underwent excision (median age 51 years, range 27-82 years). Two cases (3%; 95% confidence interval 0.3-9) were upgraded to cancer (one tubular carcinoma, one ductal carcinoma-in-situ) at excision per local pathology. Central pathology review of 76 cases confirmed pure LN in the CB in all but two cases. In one case, the tubular carcinoma identified at excision was also found in the CB specimen, and in the other, LN was not identified, yielding an upgrade rate of one case (1%; 95% CI 0.01-7) by central pathology review. CONCLUSIONS: In this prospective study of 77 patients with pure LN on CB, the upgrade rate was 3% by local pathology and 1% by central pathology review, demonstrating that routine excision is not indicated for patients with pure LN on CB and concordant imaging findings.
Authors: L Liberman; M Sama; B Susnik; P P Rosen; L R LaTrenta; E A Morris; A F Abramson; D D Dershaw Journal: AJR Am J Roentgenol Date: 1999-08 Impact factor: 3.959
Authors: Michelle Bonnett; Tracie Wallis; Michelle Rossmann; Nat L Pernick; David Bouwman; Kathryn A Carolin; Daniel Visscher Journal: Mod Pathol Date: 2003-02 Impact factor: 7.842
Authors: Lavinia P Middleton; Shakeitha Grant; Tanya Stephens; Carol B Stelling; Nour Sneige; Aysegul A Sahin Journal: Mod Pathol Date: 2003-02 Impact factor: 7.842
Authors: Miraj G Shah-Khan; Xochiquetzal J Geiger; Carol Reynolds; James W Jakub; Elizabeth R Deperi; Katrina N Glazebrook Journal: Ann Surg Oncol Date: 2012-07-31 Impact factor: 5.344
Authors: Chandandeep S Nagi; James E O'Donnell; Mikhail Tismenetsky; Ira J Bleiweiss; Shabnam M Jaffer Journal: Cancer Date: 2008-05-15 Impact factor: 6.860
Authors: Michelle C Foster; Mark A Helvie; Nancy E Gregory; Murray Rebner; Alexis V Nees; Chintana Paramagul Journal: Radiology Date: 2004-04-22 Impact factor: 11.105
Authors: Valerie P Bauer; Beth Ann Ditkoff; Freya Schnabel; David Brenin; Mahmoud El-Tamer; Suzanne Smith Journal: Breast J Date: 2003 Jan-Feb Impact factor: 2.431
Authors: Xiaoxian Li; Zhongliang Ma; Toncred M Styblo; Cletus A Arciero; Haibo Wang; Michael A Cohen Journal: Breast Cancer Res Treat Date: 2020-10-17 Impact factor: 4.872
Authors: Beth T Harrison; Faina Nakhlis; Deborah A Dillon; T Rinda Soong; Elizabeth P Garcia; Stuart J Schnitt; Tari A King Journal: Mod Pathol Date: 2020-01-13 Impact factor: 7.842
Authors: M Gabriela Kuba; Melissa P Murray; Kristen Coffey; Catarina Calle; Monica Morrow; Edi Brogi Journal: Mod Pathol Date: 2021-04-06 Impact factor: 7.842